PMID- 34352379
OWN - NLM
STAT- MEDLINE
DCOM- 20211103
LR  - 20211103
IS  - 1556-1380 (Electronic)
IS  - 1556-0864 (Linking)
VI  - 16
IP  - 11
DP  - 2021 Nov
TI  - Well-Differentiated Bronchopulmonary Neuroendocrine Tumors: More Than One Entity.
PG  - 1810-1820
LID - S1556-0864(21)02335-2 [pii]
LID - 10.1016/j.jtho.2021.07.020 [doi]
AB  - INTRODUCTION: Until now, well-differentiated bronchopulmonary neuroendocrine 
      tumors (bpNET) occurring either sporadically (sp-bpNET) or in the context of 
      multiple endocrine neoplasia type 1 (MEN1) and diffuse idiopathic pulmonary 
      neuroendocrine cell hyperplasia (DIPNECH) are regarded as similar entities. 
      However, in contrast to sp-bpNET: MEN1-related and DIPNECH-related bpNET rarely 
      metastasize or lead to bpNET-related death. We aimed to describe and compare the 
      course of the disease of sp-bpNET, DIPNECH- and MEN1-related bpNET. METHODS: All 
      patients with histologically confirmed MEN1-related bpNET from the DutchMEN Study 
      Group database (1990-2017), patients with resected sp-bpNET and DIPNECH patients 
      referred to a Dutch European Neuroendocrine Tumor Society center between 2000 and 
      2018 were included. Fisher's exact test was used for comparison between groups. 
      The primary end point was disease-specific mortality (DSM). Kaplan-Meier and 
      logrank test were used to compare survival. Cox regression was used to identify 
      risk factors for DSM in the sp-bpNET subgroup. RESULTS: We included 112 sp-bpNET, 
      29 MEN1, and 27 DIPNECH patients. Tumor classification was similar across 
      subgroups. A total of 20 patients (18%) with sp-bpNET died because of bpNET, 
      compared with none in the MEN1 group and DIPNECH group. Median disease-specific 
      survival was 12.3 (confidence interval: 6.3-18.3) years for patients with 
      sp-bpNET, and not estimable for the other subgroups (p < 0.001). Differences in 
      baseline characteristics did not explain worse survival in sp-bpNET. Tumor 
      classification and age at diagnosis were independent risk factors for DSM in 
      sp-bpNET. CONCLUSIONS: Patients with sp-bpNET have a significantly higher DSM 
      compared with MEN1 or DIPNECH-related bpNET, unexplained by differences in 
      baseline characteristics. This implies that not all bpNET are similar entities.
CI  - Copyright (c) 2021 International Association for the Study of Lung Cancer. 
      Published by Elsevier Inc. All rights reserved.
FAU - van den Broek, Medard F M
AU  - van den Broek MFM
AD  - Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The 
      Netherlands.
FAU - Levy, Sonja
AU  - Levy S
AD  - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
FAU - Buikhuisen, Wieneke A
AU  - Buikhuisen WA
AD  - Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
FAU - Dijke, Kim
AU  - Dijke K
AD  - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
FAU - Hartemink, Koen J
AU  - Hartemink KJ
AD  - Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
FAU - van Leeuwaarde, Rachel S
AU  - van Leeuwaarde RS
AD  - Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The 
      Netherlands.
FAU - Vriens, Menno R
AU  - Vriens MR
AD  - Department of Endocrine Surgical Oncology, University Medical Center Utrecht, 
      Utrecht, The Netherlands.
FAU - Tesselaar, Margot E T
AU  - Tesselaar MET
AD  - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
FAU - Valk, Gerlof D
AU  - Valk GD
AD  - Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The 
      Netherlands. Electronic address: g.d.valk@umcutrecht.nl.
CN  - DutchMEN Study Group
LA  - eng
PT  - Journal Article
DEP - 20210802
PL  - United States
TA  - J Thorac Oncol
JT  - Journal of thoracic oncology : official publication of the International 
      Association for the Study of Lung Cancer
JID - 101274235
SB  - IM
MH  - Humans
MH  - *Lung Diseases
MH  - *Lung Neoplasms
MH  - *Neuroendocrine Tumors
MH  - *Precancerous Conditions
OTO - NOTNLM
OT  - Bronchopulmonary neuroendocrine tumor (NET)
OT  - Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)
OT  - Multiple endocrine neoplasia type 1 (MEN1)
OT  - Sporadic
OT  - Survival
FIR - de Herder, Wouter
IR  - de Herder W
FIR - Dekkers, Olaf
IR  - Dekkers O
FIR - van de Ven, Annenienke
IR  - van de Ven A
FIR - Havekes, Bas
IR  - Havekes B
FIR - Drent, Madeleine
IR  - Drent M
FIR - Bisschop, Peter
IR  - Bisschop P
FIR - Zandee, Wouter
IR  - Zandee W
FIR - Valk, Gerlof
IR  - Valk G
EDAT- 2021/08/06 06:00
MHDA- 2021/11/04 06:00
CRDT- 2021/08/05 20:17
PHST- 2021/04/09 00:00 [received]
PHST- 2021/06/21 00:00 [revised]
PHST- 2021/07/02 00:00 [accepted]
PHST- 2021/08/06 06:00 [pubmed]
PHST- 2021/11/04 06:00 [medline]
PHST- 2021/08/05 20:17 [entrez]
AID - S1556-0864(21)02335-2 [pii]
AID - 10.1016/j.jtho.2021.07.020 [doi]
PST - ppublish
SO  - J Thorac Oncol. 2021 Nov;16(11):1810-1820. doi: 10.1016/j.jtho.2021.07.020. Epub 
      2021 Aug 2.